Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-257

Sanofi has a few Phase II and Phase III trial ongoing for Asthma and COPD.

It appears a lot is riding on their (only) flagship product, Dupixent for respiratory ailments. Resapp fits like a glove to aid in their research capabilities and bring their trial to endpoints at a much faster pace. In my opinion Sanofi collaboration with Resapp to develop a standalone App is not only for direct to Consumer model (to check for drug adherence and also screening) , but also to aid in R&D projects.

If you dig deeper, Sanofi's collaborated with Science 37 for virtual trials, instead of getting the trial subjects to the location, to trial in Real World setting. I won't be surprised if they integrate Resapp algo into Science 37 to conduct trials in home setting . This also adheres well with FDA's Real World Evidence ( RWE) programs where they look favorably into companies which can prove their drug is suitable in Real world setting.

I was reading somewhere the Dupixent is expected to bring revenue in Billions out of which 30% could be related to treat Respiratory conditions.


Above all based on my research and opinions formed based on that. Please DYOR